A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
Titel:
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
Auteur:
Reck, Martin Krzakowski, Maciej Chmielowska, Ewa Sebastian, Martin Hadler, Dietrich Fox, Tara Wang, Qiang Greenberg, Jon Beckman, Robert A. von Pawel, Joachim